

Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

BAYER AKTIENGESELLSCHAFT

Form 6-K

January 31, 2002

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of January, 2002

Bayer Aktiengesellschaft
(Exact name of registrant as specified in its charter)

Bayerwerk, Gebaude W1
D-51368 Leverkusen
Germany
(Address of principal executive offices)

Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by
furnishing information contained in this Form is also
thereby furnishing information to the
Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82- N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Bayer Aktiengesellschaft
(Registrant)

Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

Date: January 31, 2002

By: /s/ ALEXANDER ROSAR

Name: Dr. Alexander Rosar
Title: Head of Investor Relations

/s/ AXEL STEIGER

Name: Dr. Axel Steiger
Title: Legal Counsel

EXHIBIT INDEX

1. One English-language version of a press release dated January 31, 2002, announcing acceptance by the European Medicinal Evaluation Agency of Bayer's filing of a marketing authorization application for vardenafil, a new drug for the treatment of erectile dysfunction.

2. One English-language version of a press release dated January 31, 2002, announcing the designated management group of Bayer CropScience AG, Bayer's planned new subsidiary.